Laboratory of Bacteriology, Complexo Hospital de Clínicas, Universidade Federal do Paraná, Rua Padre Camargo, 280 - Alto da Glória, CEP: 80.062-240, Curitiba, Paraná, Brazil.
Infectious Diseases Unit, Complexo Hospital de Clínicas, Universidade Federal do Paraná, Rua General Carneiro, 181 - Alto da Glória, CEP: 80.060-900, Curitiba, Paraná, Brazil.
Anaerobe. 2020 Aug;64:102238. doi: 10.1016/j.anaerobe.2020.102238. Epub 2020 Jul 24.
Clostridioides (Clostridium) difficile is the main etiology underlying antibiotic-associated diarrhea (AAD). Still, few Brazilian data are available on this infection. The aims of this multicenter study were to identify the prevalence, clinical characteristics, and outcomes of C. difficile infection (CDI) in patients with antibiotic associated diarrhea at eight hospitals in Curitiba, southern Brazil, during the years 2017-2019. Stool samples were tested using enzyme immunoassay for glutamate dehydrogenase antigen (GDH) and A/B toxins. Positive GDH samples were further evaluated by real-time polymerase chain reaction (PCR) for the presence of genes encoding toxin B (tcdB), binary toxin (cdt), and marker of hypervirulent C. difficile strain (tcdC deletion). The prevalence of CDI in 351 patients with AAD included in the study was 17.7% (n = 62). Among the CDI cases, tcdB was positive in all 62 stool samples, while cdt was positive in 10 samples, and tcdC deletion was positive in only two. Carriage of carbapenem-resistant Gram-negative bacilli, previous hospitalization, and use of broad-spectrum cephalosporin and carbapenem were associated with CDI. Among patients with CDI, 64.5% presented with severe diarrhea, and 8% (5/62) progressed with colitis and required intensive care. The 30-day mortality was 24% (15/62), and the CDI-associated mortality was 4.8% (3/62). Overall, 83.8% (52/62) of the patients achieved primary cure, and 20.8% of the evaluated patients (10/48) presented CDI recurrence. The treatment administered was not significantly associated with the 60-day recurrence or mortality. In conclusion, we reported in this study data of prevalence and recurrence rates of CDI in patients with AAD and evaluated the number of severe cases and infection-related mortality, which were up to now unknown in Southern Brazilian hospitals.
艰难梭菌(Clostridium)是抗生素相关性腹泻(AAD)的主要病因。然而,关于这种感染,巴西的数据很少。本多中心研究的目的是在 2017 年至 2019 年期间,在巴西南部库里蒂巴的八家医院,确定 AAD 患者中艰难梭菌感染(CDI)的流行率、临床特征和结局。使用酶免疫测定法(GDH)和 A/B 毒素检测粪便样本中的谷氨酸脱氢酶抗原(GDH)。对阳性 GDH 样本进一步通过实时聚合酶链反应(PCR)检测编码毒素 B(tcdB)、二元毒素(cdt)和高毒力艰难梭菌株标志物(tcdC 缺失)的基因。在纳入研究的 351 例 AAD 患者中,CDI 的患病率为 17.7%(n=62)。在 CDI 病例中,62 份粪便样本均为 tcdB 阳性,10 份样本为 cdt 阳性,仅 2 份样本为 tcdC 缺失阳性。携带耐碳青霉烯类革兰阴性杆菌、既往住院、使用广谱头孢菌素和碳青霉烯类药物与 CDI 相关。在 CDI 患者中,64.5%表现为严重腹泻,8%(5/62)进展为结肠炎并需要重症监护。30 天死亡率为 24%(15/62),CDI 相关死亡率为 4.8%(3/62)。总体而言,83.8%(52/62)的患者达到了主要治愈,48 例评估患者中有 20.8%(10/48)出现 CDI 复发。接受的治疗与 60 天复发或死亡率无显著相关性。总之,本研究报告了 AAD 患者中 CDI 的流行率和复发率数据,并评估了严重病例和感染相关死亡率的数量,这在巴西南部医院以前是未知的。